Tirzepatide's GLP-1 and GIP dual action: what it means for weight loss

Step 1: what GLP-1 and GIP actually are

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones, chemical signals your gut releases after you eat. Their job, in broad terms, is to tell the pancreas to produce insulin, dampen appetite, and coordinate how quickly nutrients enter the bloodstream. They do this through different receptors, in slightly different tissues, with different timing profiles.

Before tirzepatide, GLP-1 receptor agonists such as semaglutide worked along one of these pathways. Researchers observed that GIP receptors were present not just in the pancreas but in fat tissue and the brain, and that activating them alongside GLP-1 receptors produced a larger appetite-suppressing signal than either alone. You can explore the specific role that GIP plays in more depth on our page about tirzepatide and the GIP receptor.

Tirzepatide was engineered as a single molecule that binds to both receptor types, and if you want a full introduction to how that works you can read more on our GLP-2 and tirzepatide page. It is sometimes described as a "twincretin" in the research literature, though the licensed name simply reflects its pharmacological class: a dual GIP and GLP-1 receptor agonist.

Step 2: how the two pathways divide the work

Once injected, tirzepatide circulates and attaches to GLP-1 receptors in the gut wall, the brainstem, and the hypothalamus. This slows gastric emptying (food leaves the stomach more gradually) and sends satiety signals to the brain. Most people find they feel full sooner and stay full longer. Nausea is the most common early side effect for this reason: the stomach is adjusting to a slower emptying rate.

Simultaneously, tirzepatide binds GIP receptors, which are expressed in adipose (fat) tissue and in regions of the brain involved in energy balance. The GIP component appears to reduce the drive to seek food at a neurological level, complementing rather than duplicating the GLP-1 signal. The two pathways are additive, not redundant. This is why the clinical outcomes for tirzepatide exceeded those seen with GLP-1-only medicines in head-to-head comparison: in the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity and no diabetes.

For a broader look at how the GLP-1 side of this equation works specifically with tirzepatide, our GLP-1 and tirzepatide page covers that mechanism in isolation.

Step 3: what this means for you in practice

The dual mechanism translates into practical changes most people notice within the first few weeks of treatment: smaller portions feel sufficient, the mental pull toward snacking diminishes, and energy levels can shift as eating patterns stabilise. These are real physiological effects, not simply willpower.

Treatment starts at 2.5 mg, the first pen's job is to let your system adjust, not to deliver full therapeutic effect. A prescriber titrates the dose in steps from there, typically at four-week intervals, based on how you are tolerating the medicine. The full licensed range runs to 15 mg. Understanding the cost landscape for the different dose levels is useful background; our guide to Mounjaro pricing in the UK covers what private treatment typically involves at each stage.

One habit worth building early: before each new pen, check the expiry date printed on the cartridge. It takes under a minute and catches the rare case where a pen has sat in the fridge long enough to be close to its limit. Store pens at 2–8°C until use, and always read the Patient Information Leaflet for the exact room-temperature window.

The NICE technology appraisal for tirzepatide (TA1026) sets out the licensed eligibility criteria for NHS use, including BMI thresholds and qualifying conditions. Private eligibility under the SmPC is broader, starting at a BMI of 30 or 27 with a weight-related condition, but a prescriber still assesses the full clinical picture before approving treatment. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

What the dual mechanism does not change

Understanding the pharmacology does not make tirzepatide suitable for everyone, and the mechanism does not override the need for clinical assessment. Contraindications include a personal or family history of medullary thyroid carcinoma or MEN2, and people with certain gastrointestinal conditions need careful prescriber review. Pregnancy, breastfeeding, and trying to conceive are situations where these medicines are not recommended. Under-18s are outside the licensed indication entirely.

Because tirzepatide is a dual GIP and GLP-1 receptor agonist, it carries the same class-level cautions as GLP-1 medicines: tell your healthcare team before any surgical procedure, and be alert to the signs of acute pancreatitis, severe, persistent stomach pain that may spread to the back deserves prompt medical attention. For a fuller look at tirzepatide as a treatment, including eligibility, side-effect profile, and the NHS versus private routes, our Mounjaro overview is a good next step. You can also compare how the GLP-1 plus GIP approach differs from GLP-1-only treatment on our GLP-1, GIP and Mounjaro comparison page.

If you are thinking about starting treatment, our prescribers are happy to talk through whether tirzepatide suits your situation. Start your free consultation and a GPhC-registered Independent Prescriber will review your answers the same day.